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Abstract
Objective To evaluate the detection of pituitary lesions at
7.0 T compared to 1.5 T MRI in 16 patients with clinically
and biochemically proven Cushing’s disease.
Methods In seven patients, no lesion was detected on the ini-
tial 1.5 T MRI, and in nine patients it was uncertain whether
there was a lesion. Firstly, two readers assessed both 1.5 Tand
7.0 T MRI examinations unpaired in a random order for the
presence of lesions. Consensus reading with a third neurora-
diologist was used to define final lesions in all MRIs. Second-
ly, surgical outcome was evaluated. A comparison was made
between the lesions visualized withMRI and the lesions found
during surgery in 9/16 patients.
Results The interobserver agreement for lesion detection was
good at 1.5 T MRI (κ=0.69) and 7.0 T MRI (κ=0.62). In five
patients, both the 1.5 Tand 7.0 TMRI enabled visualization of
a lesion on the correct side of the pituitary gland. In three
patients, 7.0 T MRI detected a lesion on the correct side of
the pituitary gland, while no lesion was visible at 1.5 T MRI.
Conclusion The interobserver agreement of image assess-
ment for 7.0 T MRI in patients with Cushing’s disease was
good, and lesions were detected more accurately with 7.0 T
MRI.
Key Points
• Interobserver agreement for lesion detection on 1.5 T MRI
was good;
• Interobserver agreement for lesion detection on 7.0 T MRI
was good;
• 7.0 T enabled confirmation of unclear lesions at 1.5 T;
• 7.0 T enabled visualization of lesions not visible at 1.5 T.
Keywords Pituitary gland . Pituitary adenoma . Cushing’s
disease, pituitary . Pituitary ACTH hypersecretion .Magnetic
resonance imaging
Introduction
Endogenous Cushing’s syndrome is a clinical condition in
which the adrenal glands secrete excessive amounts of corti-
sol. In Cushing’s disease, which is responsible for 80–85 % of
adrenocorticotrophic hormone (ACTH)-dependent Cushing’s
syndrome, an ACTH producing adenoma located in the pitu-
itary gland stimulates the adrenal glands to secrete the exces-
sive amounts of cortisol [1]. In the majority of cases these
adenomas are microadenomas, which are challenging to diag-
nose [2]. Therefore, final diagnosis is often based on central
venous sampling and magnetic resonance imaging (MRI) [3].
In case a pituitary origin of Cushing’s syndrome is confirmed,
the treatment of choice is surgical removal of the lesion, for
which visualization of the lesion is crucial [4–6].
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Consequently, it is important to visualize the pituitary gland
with the highest possible spatial resolution, which enables
correct delineation of small anatomical structures and patho-
logical lesions.
In routine clinical practice, MRI is the preferred imaging
technique, since it can attain the highest spatial resolution,
signal-to-noise ratio (SNR), and contrast-to-noise ratio
(CNR) of the pituitary gland [7, 8]. MRI at a field strength
of 1.5 Tesla (T) is most commonly used, but pituitary
microadenomas remain undetected in 36–63 % of patients at
this field strength [9–13]. The higher attainable SNR and spa-
tial resolution at higher field strengths – for instance 3.0 T or
7.0 T – theoretically has the potential to significantly improve
the tumour detection rate [14, 15].
Recently, a high resolution 7.0 T pituitary gland MRI pro-
tocol with a 0.8 mm isotropic voxelsize was presented [16].
Feasibility was demonstrated in healthy control subjects and
case examples of patients with Cushing’s disease were given.
The aim of the current preliminary retrospective study is to
evaluate the detection of pituitary lesions with high resolution
pituitary gland imaging at 7.0 T compared to 1.5 T MRI in
patients with clinically and biochemically proven Cushing’s
disease with inconclusive lesions localization at 1.5 T MRI.
Methods
Subjects
Between January 2012 and July 2014, 16 patients with clini-
cally and biochemically proven Cushing’s disease underwent
7.0 T MRI in the University Medical Center Utrecht. Patients
were referred to Utrecht when the standard 1.5 T MRI was
inconclusive for the detection of an adenoma. An inconclusive
diagnosis was defined as no pathologies visible or as an un-
clear lesion visible, which both needed further investigation.
The institutional review board (IRB) of the University Medi-
cal Center Utrecht approved imaging at 7.0 T MRI for clinical
purposes in case lower field strength MRI was inconclusive
for diagnosis. All patients gave written informed consent. The
Radboud University Medical Center referred eight patients to
Utrecht and the remaining eight patients were patients from
the University Medical Center Utrecht. IRB approval was
obtained in both university medical centres to evaluate retro-
spectively the clinical information and 1.5 T and 7.0 T MR
images of all patients. Data of five patients was previously
published as part of clinical case examples of the high resolu-
tion pituitary protocol. [16]
Clinical evaluation
A pituitary origin of ACTH-dependent Cushing’s syndrome
was established by biochemical tests, including inferior
petrosal sinus sampling (IPSS). A detailed description of these
tests, used for diagnosis, is given in the Appendix.
Magnetic resonance imaging
Initial imaging of all patients was performed on 1.5 T MRI
systems, using a local clinical protocol for depicting the pitu-
itary gland. The protocol consisted of a pre- and post-contrast
T1-weighted turbo spin echo (TSE) sequence, a dynamic T1-
weighted TSE sequence, and a T2-weighted TSE sequence.
Note that five patients were referred from peripheral hos-
pitals. In all patients, theMRI from the peripheral hospital was
of good quality and consequently used for the current retro-
spective analysis. In six patients, the dynamic T1-weighted
TSE sequence was lacking in the protocol. Also, in six pa-
tients, a proton density-weighted sequence and in two patients
a diffusion-weighted sequence was added to the protocol.
All 7.0 T MRI examinations were performed on a 7.0 T
whole-body MRI system (Philips Healthcare, Cleveland, OH,
USA) with a 32-channel receive-coil and a volume transmit/
receive-coil (Nova Medical, Inc., Wilmington, MA, USA).
The imaging protocol was similar to the dedicated imaging
protocol previously described [16]. Briefly, the protocol
consisted of a three-dimensional (3D) T2-weighted TSE se-
quence and a 3D T1-weighted magnetization-prepared inver-
sion recovery (MPIR) TSE sequence before and after contrast
administration. Scanning parameters are demonstrated in
Table 1. A single dose, 0.1 mL/kg, gadolinium-based contrast
agent was used. Post-contrast imaging was started approxi-
mately 2 min after contrast injection. A dynamic contrast-
enhanced sequence was not performed. As described previ-
ously, these sequences were used to enable imaging with lim-
ited amounts of artefacts [16]. Susceptibility and movement
were the most disturbing artefacts due to the anatomical posi-
tion of the pituitary gland in close proximity to the sphenoid
sinus and, respectively, due to the high resolution, in combi-
nation with the relatively long duration of the sequences [16].
Table 1 Scanning parameters
T1 MPIR TSE T2 TSE
FOV (mm) 250×250×190 250×250×190
Acquired resolution (mm) 0.8×0.8×0.8 0.7×0.7×0.7
Acquired voxel size (mm3) 0.512 0.343
TR/TI (ms) 3952/1375 3200/-
TE/equivalent TE (ms) 37/19 300/58
Flip angle (degrees) 150 120
TFE/TSE factor 158 182
NSA 2 2
SENSE factor (AP x RL) 2×3 2×2.8
Duration (min:sec) 10:40 10:24
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Image analysis
Firstly, the images were evaluated by two experienced neuro-
radiologists (ThW and DR) with 25 and 8 years’ experience,
respectively. All 1.5 T and 7.0 T scans were presented to the
observers, unpaired and in a random order. Images were eval-
uated for the presence and number of lesions in the pituitary
gland and the precise location of all identified lesions. Sec-
ondly, consensus reading with a third neuroradiologist (JH),
with 10 years’ experience, was used to evaluate the differ-
ences between both first observers and to make a final deci-
sion for every MRI. All observers were masked for patient
characteristics, clinical and biochemical data, and the initial
MRI diagnoses. However, they were not masked for the diag-
nosis of Cushing’s disease.
Interobserver agreement for the presence of lesions was
evaluated with Cohen’s kappa coefficient. The kappa ranged
from 0 (no agreement) to 1 (perfect agreement) and was di-
vided into the following five categories: <0.20 (poor), 0.21 to
0.40 (fair), 0.41 to 0.60 (moderate), 0.61 to 0.80 (good), and
0.81 to 1.00 (very good). The statistical analysis was per-
formed in IBM SPSS Statistics version 20 (IBM Corporation,
Armonk, NY, USA).
Surgery
When patients underwent surgery, the macroscopic and mi-
croscopic outcome of surgery, symptom status after surgery,
and morning serum cortisol levels in the first week after sur-
gery were used to evaluate the clinical outcome of surgery.
Cure was defined as a morning serum cortisol of <0.14 μmol/
L, based on previous published literature, or as clinical remis-
sion [17]. The final results of 1.5 T MRI and 7.0 T MRI were
compared with the surgical outcome. Histopathology was not
taken into account for the current analysis because the surgical
procedure was not standardized, which might result in a poor




In total, 16 patients underwent 7.0 T MRI of the pituitary
gland. In seven patients, no lesion was detected on the initial
1.5 TMRI, and in nine patients, it was uncertain whether there
was a lesion.
Image analysis
There was absolute agreement between both observers for the
results of 1.5 T MRI scans in 11 patients. In five patients, both
observers scored the 1.5 T MRI as no pathologies, and in six
patients, both observers identified one identical lesion (n=4)
or two identical lesions (n=2). In the remaining five patients,
one observer identified a lesion, whereas the other observer
did not (n=1); both observers identified one identical lesion,
and only one observer identified a second lesion (n=2); or a
lesion in the right side of the pituitary gland was identified by
one observer, and a lesion in the left side of the pituitary gland
was identified by the second observer (n=2).
There was absolute agreement between both observers for
the results of 7.0 T MRI scans in 10 patients. In one patient,
both observers scored the 7.0 TMRI as no pathologies, and in
nine patients, both observers identified one identical lesion
(n=6), or two identical lesions (n=3). In the remaining six
patients, one observer identified a lesion, whereas the other
did not (n=5), or both observers identified one identical le-
sion, and only one observer identified a second lesion (n=1).
The probability-adjusted interobserver agreement was good
for 1.5 T MRI (κ=0.69) and for 7.0 T MRI (κ=0.62). The
results are presented in Table 1, including the initial diagnosis
on 1.5 T MRI.
After consensus reading, 13 lesions, in nine patients, were
identified on 1.5 T MRI scans, compared to 17 lesions, in 13
patients, on 7.0 T MRI. In three patients two lesions were
visible on both 1.5 T MRI and 7.0 T MRI. In two patients,
two lesions were visible only on 1.5 T MRI (n=1) or only on
7.0 T MRI (n=1). Comparison of the 1.5 T and 7.0 T results
demonstrated in 10 patients an identical diagnosis on 1.5 T
and 7.0 T. In the remaining six patients, there was discrepancy
between 1.5 Tand 7.0 T. The exact results are demonstrated in
Table 2.
Examples are given in Figs. 1 and 2. In the patient in Fig. 1,
initially no pathologies were identified on 1.5 T MRI. For the
current study, there was discrepancy between both observers
for the 1.5 T MRI, only one observer identified a lesion. On
7.0 T, however, both observers identified this lesion. This case
demonstrates that 7.0 T MRI might contribute to a more cer-
tain diagnosis.
Surgery
Transsphenoidal endoscopic microadenomectomy was per-
formed in 13 patients, and one patient underwent
transsphenoidal total hypophysectomy. An overview of the
outcome of surgery in all patients is demonstrated in Table 1.
In four patients, both sides of the pituitary gland were ex-
plored, or the side of exploration was not clearly reported by
the neurosurgeon. Since for a correct correlation with MRI, it
is crucial to know from which side a potential microadenoma
has been excised during surgery, these four patients were not
used for further analysis. For the remaining nine patients, the
right side of the pituitary gland was explored in seven patients
and the left side of the pituitary gland was explored in two
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patients. All nine patients were cured after surgery with a
morning serum cortisol level of <0.14 μmol/L after surgery.
Exact values are demonstrated in Table 1. In five patients, both
the 1.5 T and 7.0 T MRI enabled visualization of a lesion on
the correct side of the pituitary gland. In three patients, 7.0 T
MRI enabled visualization of a lesion on the correct side of the
pituitary gland, while no lesion was visible at 1.5 T MRI. In
one patient only, 1.5 T MRI detected the lesion on the correct
side of the pituitary gland. In this patient, a different lesion
was visualized at 7.0 T MRI.
Discussion
The current preliminary study demonstrated that the interob-
server agreement for the detection of microadenomas in pa-
tients with Cushing’s disease is good, both at 1.5 T MRI and
7.0 T MRI. Additionally, in five patients, 7.0 T enabled con-
firmation of an unclear lesion at 1.5 T, and in three patients,
7.0 T enabled visualization of a lesion not visible at 1.5 T.
Previous literature has demonstrated that with high field
strength 3.0 T MRI, an increased detection rate of pituitary
lesions is achieved compared to standard 1.0 and 1.5 T MRI
[15, 18, 19]. This is important as there is evidence that a
precise localization is associated with a more favourable out-
come of surgery [5, 20]. However, other studies could not
demonstrate that the cure rate is higher in patients in whom
the lesion is actually visualized before surgery [4, 18, 21].
Nevertheless, it is obvious that in patients with no visible
lesion on MRI, a more extensive surgical procedure is needed
[4].
A high spatial resolution 7.0 T MRI protocol has demon-
strated a more detailed visualization of pituitary gland anato-
my and promising results for detecting pathology [16]. Fur-
thermore, the current study has demonstrated good interob-
server agreement for both 1.5 T MRI and 7.0 T MRI, apart
from the limited experience with 7.0 TMRI of both observers.
Although the initial diagnosis on 1.5 T in all patients was
inconclusive in the current study, there was absolute
Table 2 Patient overview with MRI results after consensus
Patient Initial
diagnosis




1.5 T 1.5 T 7.0 T
1 L N L Unknownb 0.02 Yes
2 N R/L R/L R 0.05 Yes
3 R R R R <0.02 Yes
4 L L L L <0.02 Yes
5 R N N Bothc 0.2 Yes
6 R R C R <0.02 Yes
7 N N N n.a. n.a. n.a.
8 N N N n.a. n.a. n.a.
9 L L L n.a. n.a. n.a.
10 N N R/L R <0.02 Yes
11 N N R R <0.02 Yes
12 L/R L L/C Bothc 0.12 Yes
13 N N R R 0.05 Yes
14 L/R L L Bothc 0.72 No
15 N R/L L L 0.02 Yes
16 R R/C R/C R <0.02 Yes
Results are lesions found right (R), left (L), or central (C) in the pituitary
gland or no pathologies (N), or a combination of those. n.a. = not appli-
cable, these patients have not had surgery yet; a Cure is defined as morn-
ing serum cortisol of <0.14 μmol/L or clinical remission; b From these
patients, it is unknown from which side of the pituitary gland tissue has
been excised; c from these patients, tissue is excised from both sides of
the pituitary gland; morning serum cortisol (μmol/L) is determined in the
week post-surgery
Fig. 1 The 1.5 T and 7.0 T MR
images of a 56-year-old woman
with Cushing’s disease. The
lesion marked in the 1.5 T images
(white arrowhead) was identified
by only one of the two observers.
Note that this lesion was only
visible on one slice. After
consensus with a third observer,
the final decision was Bno
lesions^. The lesion marked in the
7.0 T images (white arrow) was
identified by both observers
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agreement for the diagnosis on those images in 11 patients.
This high rate of agreement suggests that consensus reading in
clinical practice might also confirm inconclusive diagnoses.
However, the high spatial resolution of 7.0 T MRI enables
visualization more detail than standard 1.5 T MRI, which
might result in more visible lesions.
The current study has demonstrated that high resolution
7.0 T MRI allows visualization of more pituitary lesions com-
pared to 1.5 T MRI. In the small series of patients presented,
the number of lesions visualized with 7.0 T MRI is higher
compared to 1.5 T MRI. In addition, in the majority of cases
the additional findings of 7.0 T MRI confirmed the unclear
lesion on the initial 1.5 T MRI or enabled visualization of the
actual lesion, which was not visible at 1.5 T MRI. Conse-
quently, we suggest that the predictive value of lesion detec-
tion on 7.0 T MRI is promising. However, it is important to
note that with an increasing spatial resolution the chance of
false-positive findings – incidentalomas – also increases.
Incidentalomas occur in 10–20 % of the patients, which po-
tentially results in a higher percentage of false-positive find-
ings with the improved lesion detection rate at higher field
strengths [22, 23].
In addition to pituitary lesion detection, the visualization of
the surrounding pituitary anatomy may be used for neurosur-
gical planning [14, 24–26]. Pituitary gland MRI at 3.0 T has
demonstrated to improve the evaluation of the parasellar anat-
omy and the relation of the lesion to the adjacent structures
[14]. However, 7.0 T MRI is expected to provide an even
more detailed overview of the parasellar anatomy [27–29].
Nevertheless, with the current retrospective analysis we did
not evaluate the parasellar anatomy. Consequently, it was not
possible to evaluate the additional value for the performed
surgical procedures.
The current study has several limitations. Firstly, a poten-
tially confounding factor is the selection bias that is introduced
by only imaging patients at 7.0 T MRI when the 1.5 T MRI
was inconclusive. This means that only the difficult Cushing’s
disease cases were included in the current study. Therefore, it
is important to notice that a conclusive Cushing’s disease di-
agnosis may be challenging even for an experienced neurora-
diologists. Secondly, different imaging protocols were used
for clinical 1.5 T MRI of the pituitary gland because 1.5 T
pituitary imaging was part of routine clinical practice of dif-
ferent referring hospitals. This implies that different vendors
of MRI scanners and different scan parameters were used.
Furthermore, the clinically acquired sequences were not equal
in all patients. This might have influenced our results in favour
of the 7.0 T MRI protocol. Still, we feel that the current study
gives a realistic view of what can be expected from standard
1.5 T pituitary glandMRI compared with high resolutionMRI
at 7.0 T. Thirdly, the reports of the surgical procedure were
incomplete in some patients. From these patients it is known
whether they were cured after surgery or not. However, it
remains unknown from which side of the pituitary gland the
microadenoma was removed, hindering a comparison be-
tween MRI and surgery in four patients. Fourthly, in two pa-
tients no lesion was identified initially on 1.5 T MRI (Fig. 1)
and in two other patients, a lesion was detected initially. How-
ever, after consensus reading, a lesion was actually identified
in the first two patients, and no lesion was detected in the
second two patients. This might indicate that consensus read-
ing could also be a solution for initially undetectable pituitary
microadenomas on 1.5 T MRI. Fifthly, a dedicated dynamic
contrast enhanced (DCE) sequence was lacking in the current
7.0 T MRI protocol, whereas a DCE sequence at 1.5 T MRI
was present in 10 patients. Previous literature demonstrates
the clinical advantages of DCE imaging in lesion detection
in patients with Cushing’s disease [30, 31]. Addition of a
DCE sequence with high spatial resolution might increase
the detection rate of the smallest lesions. Therefore, a DCE
sequence might increase the interobserver agreement as well.
Finally, the current retrospective analysis lacks the involve-
ment of 3.0 T MRI. The improvement in SNR and the better
spatial resolution by using 3.0 T MRI appears to establish a
clear advantage in the localization of microadenomas and in
the presurgical planning in patients with Cushing’s disease
Fig. 2 The transversal 7.0 Tesla
T1 MPIR TSE images before and
after contrast enhancement of a
42-year-old male diagnosed with
Cushing’s disease. On the 1.5 T
images, not demonstrated, there
was no lesion detected. On 7.0 T
MRI there was a lesion detected
(arrowhead) in the left side of the
pituitary gland. During surgery,
an ACTH producing
microadenoma was removed
from the left side of the pituitary
gland
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[15, 19]. Still, 3.0 T MRI has not yet supplanted 1.5 T MRI as
standard clinical workup for patients with Cushing’s disease
and a suspected pituitary microadenoma. A large-scale head-
to-head comparison of 1.5 T, 3.0 T, and 7.0 T MRI with ded-
icated scanning protocols is needed to evaluate the actual clin-
ical advantages from high spatial resolution MRI in Cushing’s
disease. A prospective study should include an exact descrip-
tion of the surgical procedure, including the benefit of neuro-
surgical guidance based on the available detailed MR images.
To conclude, the interobserver agreement of image assess-
ment for 7.0 TMRI in patients with Cushing’s disease was good
and lesions were detected more accurately with 7.0 T MRI.
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